ARPIM appoints new president and board

Newsroom 09/01/2013 | 15:24

Efthymios (Makis) Papataxiarchis, managing director of Johnson & Johnson Romania and Janssen Romania pharmaceutical companies, was named the president of the Romanian Association of International Pharmaceuticals Producers (ARPIM), replacing Regis Lhomme, general director of Amgen Romania.

Makis has worked in the pharmaceuticals sector for 17 years and held management positions in marketing and sales. He moved to Johnson & Johnson after having worked for 5 years at Novartis. He was previously APRIM vice-president.

“The main objective of my mandate as ARPIM president is to strengthen the relationship between the pharmaceutical industry and the society,” said Makis. “We want to continue a relationship based on trust and to contribute to a more transparent healthcare system on decision making.”

Makis is a Doctor in Pharmaceutical Sciences and holds a Masters degree in Pharmacology.

The new ARPIM board:

Regis Lhomme, vice-president – general director Amgen Romania

Radu Rasinar, vice-president, general director Astra Zeneca

Elena Mitova, member – general director Novartis

Calin Galseanu, member – general director BMS

Pascal Prigent, member – general director GSK

Luca Visini – member – general director Eli Lilly

Dan Zaharescu – executive director ARPIM

Ovidiu Posirca

BR Magazine | Latest Issue

Download PDF or read online: July 2023 Issue | Business Review Magazine

The July 2023 issue of Business Review Magazine is now available in digital format, featuring the main cover story titled “At a Crossroads: Budget Deficit Endangering Romania’s Economic
Newsroom | 31/07/2023 | 14:14

    You will receive a download link for the latest issue of Business Review Magazine in PDF format, based on the completion of the form below.

    I agree with the Privacy policy of

    I agree with the storage and handling of my data by

    Advertisement Advertisement
    Close ×

    We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

    Accept & continue